Stock XNCR XENCOR, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Xencor, Inc.

Equities

XNCR

US98401F1057

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-02 pm EDT 		5-day change 1st Jan Change
18.26 USD -4.00% Intraday chart for Xencor, Inc. -5.63% -13.99%
Jun. 14 Raymond James Adjusts Price Target on Xencor to $40 From $58, Maintains Strong Buy Rating MT
Jun. 14 BMO Capital Adjusts Xencor's Price Target to $32 From $34, Keeps Outperform Rating MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Disclosure Of Antibody's Equivalents Not Necessary To Satisfy Written Description And Indefiniteness Requirements For A Means-Plus-Function Claim Term
AQ
InnoCare Announces the Acceptance of Biologics License Application for Tafasitamab in Combination with Lenalidomide for the treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Adult Patients
AQ
Raymond James Adjusts Price Target on Xencor to $40 From $58, Maintains Strong Buy Rating
MT
BMO Capital Adjusts Xencor's Price Target to $32 From $34, Keeps Outperform Rating
MT
RBC Trims Price Target on Xencor to $31 From $32, Maintains Outperform, Speculative Risk Rating
MT
Wedbush Cuts Price Target on Xencor to $34 From $36, Maintains Outperform Rating
MT
Xencor to Regain Exclusive Global Rights to CD20 x CD3 Bispecific T-Cell Engager
MT
Xencor : J&J's Janssen Termintates Rights to Plamotamab
DJ
Xencor Regains CD20 x CD3 Bispecific T-Cell Engager
BU
Xencor, Inc. Regains CD20 x CD3 Bispecific T-Cell Engager
CI
The Appeals Review Panel's In Re Xencor Decision: The USPTO Provides Its Position On Written Description And Means-Plus-Function Claims
AQ
Transcript : Xencor, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 01:40 PM
Wedbush Adjusts Xencor's Price Target to $36 From $34, Keeps Outperform Rating
MT
Xencor: Q1 Earnings Snapshot
AQ
Earnings Flash (XNCR) XENCOR Reports Q1 Revenue $12.8M
MT
Xencor Reports First Quarter 2024 Financial Results
BU
Xencor, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
BTIG Cuts Price Target on Xencor to $38 From $56, Keeps Buy Rating
MT
Xencor Names Bart Cornelissen as Chief Financial Officer
MT
Xencor Appoints Bart Cornelissen as Chief Financial Officer
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. XNCR Stock
  4. News Xencor, Inc.